Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops targeted oncology and immunology therapies. Based in California, the company focuses on treatments that modulate immune cell maturation and function to combat cancers and immune diseases. Its lead clinical program is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase) and is being evaluated for peripheral T-cell lymphoma and atopic dermatitis. The company's broader pipeline includes mupadolimab, an anti-CD73 antibody, and ciforadenant, a small molecule checkpoint inhibitor. While Corvus operates primarily in the United States, it has expanded its geographic footprint through a partnership with Angel Pharmaceuticals to develop and commercialize its clinical-stage candidates in Greater China.
